FDA proposal to restrict compounded GLP-1 medicines raises safety concerns for pharmacists

Pharmacists express heightened concerns over the safety, authenticity, and regulation of compounded GLP-1 medicines as the FDA moves towards tighter rules amid rising demand and market complexities.

Pharmacists are increasingly being asked to help patients navigate a fast-changing market for compounded GLP-1 medicines as the US Food and Drug Administration moves towards tighter rules on semaglutide, tirzepatide and liraglutide. In a follow-up discussion with Drug Topics, three pharmacy practice educators at the Massachusetts College of Pharmacy and Health Sciences said the biggest concerns now centre on authenticity, safe handling and whether patients know where their medicine is really coming from. The FDA has proposed excluding the three drugs from the 503B bulks list, a step that would limit the ability of outsourcing facilities to compound them from bulk substances, while still leaving room for patient-specific compounding in some circumstances.

Hailey Choi said reputable compounders may use quality controls such as source verification, certificates of analysis, potency testing, sterility checks and lot tracking, but patients are increasingly asking whether a pharmacy is legitimate and whether the product has been shipped and stored correctly. Spencer Casella said the popularity of GLP-1s has been fuelled by high demand, steep costs and gaps in insurance coverage, which pushed some patients towards compounded versions during shortages. Jana Murry said pharmacists now face heightened concern about counterfeit products and rapid-scale production, and should keep patient safety ahead of speed, profit and convenience.

The educators said their confidence in the GLP-1 class itself has not changed. Choi said FDA-approved therapies still have strong evidence across diabetes, obesity and cardiovascular disease, but the episode has underlined how important the delivery system is, from prescribing and titration to patient education and product quality. Casella drew a sharp line between approved medicines and compounded copies, saying pharmacists should stay objective and put safety first.

Telehealth and mail-order distribution have widened access, especially for patients who struggle to find local obesity care, but Choi said that convenience can also make it harder to know who is prescribing, compounding and dispensing the medication. Murry warned that online searches around weight loss can expose patients to a mix of useful, misleading and malicious information, making source-checking essential. Reuters has reported that the FDA’s proposal is aimed at outsourcing facilities under section 503B, not at banning all forms of compounding, but the agency’s move reflects a broader push to separate legitimate care from grey-market supply chains.

Looking ahead, Choi said access is likely to shift towards FDA-approved products, manufacturer self-pay programmes, broader insurance coverage and new competitors if the exclusion is finalised. Even so, she said compounded medicines may still have a role when there is a documented clinical need. The larger problem, in her view, remains affordability: if lower-cost access shrinks without better coverage, some patients may drift towards less regulated options. Casella said access will continue to evolve regardless of the FDA’s final decision.

The pharmacists also urged close watch on future enforcement around telehealth marketing, API sourcing and product quality, as well as the growing online promotion of investigational products such as retatrutide and cagrilintide, which are not approved by the FDA but are already being marketed to consumers. Murry said suppliers will need tighter vigilance to ensure products are made, shipped and delivered safely. For pharmacists, the task is becoming less about whether GLP-1s work and more about whether each product is legitimate, properly prepared, correctly dosed and safe to use.